Ann: Annual Report to shareholders, page-2

Such an under rated stock, look at the revenue figures -



250% growth vs Prior year and that was during COVID!
What amazes me the most is sales from Korea have 3x in 12months, again during COVID.

Few new buy orders coming in, anyone that's looked the balance sheet here will spot the goodies.
No debt, 12months+ cash on hand, growing revenue, ex ResMed CFO on the Board, new distributors, manufacturing scaled up, very attractive margins, large TAM, new products in the pipeline..

Soak up those shares under 50 while it lasts.